Revenue Recognition (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended				6 Months Ended		12 Months Ended
	Jul. 31, 2021	Feb. 28, 2019	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2019	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2019	Aug. 31, 2019
Refunds of revenues previously deferred								$ 10,000
Deferred revenue, Long-term			$ 20,721				$ 20,721					$ 21,318
Other assets			21,502				21,502					18,820
Deferred revenue			36,730	$ 34,209			36,730	34,209				28,722	$ 72,930
Deferred revenue, current portion			16,009				16,009					7,404
Total revenues			198,200	142,026			392,333	294,342
Deferred revenue, long-term portion			20,721				20,721					21,318
Revenue recognized during the period that was included in deferred revenues at the beginning of the period							5,757	30,839
Product
Revenue recognized			1,800	1,700			3,400	3,000
Cost of revenues			108,756	75,527			211,426	141,359
Total revenues			194,582	139,647			$ 384,584	260,031
Product | Minimum
Billing collection period (in months)							9 months
Product | Maximum
Billing collection period (in months)							12 months
Licensing and other
Cost of revenues			481	585			$ 1,026	1,566
Total revenues			3,618	$ 2,379			7,749	$ 34,311
Genetic testing services
Revenue recognized during the period that was included in deferred revenues at the beginning of the period							$ 1,900
Qiagen
Proceeds from license agreement										$ 5,000
Agreement term							10 years
Revenue, remaining performance obligation										40,000
Qiagen | Volume, regulatory and commercial milestones
Revenue, remaining performance obligation										$ 10,000
Qiagen | Other licensing and other revenue
Refunds of revenues previously deferred					$ 10,000
Deferred revenue					$ 28,600
Laboratory distribution partners | Product | Minimum
Billing collection period (in months)							2 months
Laboratory distribution partners | Product | Maximum
Billing collection period (in months)							3 months
BGI Genomics
Proceeds from license agreement		$ 50,000				$ 35,600
Receivable						$ 2,500
Agreement term		10 years
Deferred revenue, current portion			6,400				$ 6,400
BGI Genomics | Sequencing services
Other assets														$ 6,000
BGI Genomics | Sequencing products
Other assets														4,000
BGI Genomics | Sequencing products and services
Other assets														$ 10,000
BGI Genomics | Milestone payments
Receivable											$ 5,000
Foundation Medicine ("FMI")
Proceeds from license agreement									$ 16,300
Deferred revenue, current portion			1,400				1,400
Foundation Medicine ("FMI") | Milestone payments
Proceeds from license agreement	$ 1,000
Receivable											$ 2,000
Deferred revenue, current portion			$ 1,000				$ 1,000					$ 2,000
Foundation Medicine ("FMI") | Upfront licensing fees and prepaid revenues
Initial transaction price															$ 13,300
Foundation Medicine ("FMI") | Developmental, regulatory, and commercial milestones
Initial transaction price															$ 32,000
Foundation Medicine ("FMI") | Developmental performance milestones
Proceeds from license agreement									3,000
Foundation Medicine ("FMI") | Licensing fees and prepaid revenue
Proceeds from license agreement									$ 13,300